" class="no-js "lang="en-US"> Harshit Shah Archives - Medtech Alert
Wednesday, March 29, 2023

Breaking News

PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs Genialis Raises $13M in Financing to Build Clinical Biomarkers that Predict Patient Response Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer MIMETAS and Astellas Enter into Strategic Partnership First New Life-extending NHS Treatment for Incurable Cervical Cancer in Almost 15 Years Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck FLASH Proton Therapy Clinical Trial Begins on Cancers Involving Bones in the Chest Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize T Cell Therapies

Sort by:

Date

Top Post

NHS Slashes Longest Elective and Cancer Waits for Patients | MTA

NHS Slashes Longest Elective and Cancer Patient Waiting Lists

The number of people waiting over 18 months for NHS care has fallen again despite […]

Read more

Appointments

 Spring Health Announces Harshit Shah as New Chief Technology Officer | Pharmtech Focus

Spring Health Announces Harshit Shah as New Chief Technology Officer

Spring Health, a leading provider of behavioral health benefits with the most comprehensive solution for […]

  1. PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs

    News

     Read more
  2. Genialis Raises $13M in Financing to Build Clinical Biomarkers that Predict Patient Response

    Fundraising

     Read more
  3. Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment

    Diseases

     Read more
  4. Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

    News

     Read more
  5. Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer

    Drug Development

     Read more